Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

World Tumor Necrosis Factor Receptor Superfamily Member 16 Pipeline Report 2016 Featuring Dompe Farmaceutici S.p.A., PharmatrophiX, Inc. & Sanofi - Research and Markets

Research and Markets
Posted on: 20 Sep 16

Research and Markets has announced the addition of the "Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) - Pipeline Review, H2 2016" report to their offering.

Tumor Necrosis Factor Receptor Superfamily Member 16 Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4.

Tumor Necrosis Factor Receptor Superfamily Member 16 pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.The molecules developed by Companies in Phase II and Preclinical stages are 2 and 3 respectively.

Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H2 2016, outlays comprehensive information on targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

Key Topics Covered:

  1. Introduction
  2. Tumor Necrosis Factor Receptor Superfamily Member 16 Overview
  3. Therapeutics Development
  4. Pipeline Products for Tumor Necrosis Factor Receptor Superfamily Member 16 - Overview
  5. Pipeline Products for Tumor Necrosis Factor Receptor Superfamily Member 16 - Comparative Analysis
  6. Tumor Necrosis Factor Receptor Superfamily Member 16 - Therapeutics under Development by Companies
  7. Tumor Necrosis Factor Receptor Superfamily Member 16 - Therapeutics under Investigation by Universities/Institutes
  8. Tumor Necrosis Factor Receptor Superfamily Member 16 Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Tumor Necrosis Factor Receptor Superfamily Member 16 - Products under Development by Companies
  13. Tumor Necrosis Factor Receptor Superfamily Member 16 - Products under Investigation by Universities/Institutes
  14. Tumor Necrosis Factor Receptor Superfamily Member 16 - Companies Involved in Therapeutics Development
  • Dompe Farmaceutici S.p.A.
  • PharmatrophiX, Inc.
  • Sanofi

For more information about this report visit http://www.researchandmarkets.com/research/g9twrl/tumor_necrosis

Related Topics: Oncology Drugs

View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005826/en/

Business Wire
www.businesswire.com

Last updated on: 20/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.